ERBB2 and cancer: In the absence of synchronous nodal metastases, their study bears much significance because negative genic switch of HER2 in residual tumors after NAC poses a challenge to the utilization of targeted therapy with a proportion of patients whose cancer lost HER2 expression after NAC in their study not receiving trastuzumab.